## Carlo Torti

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1259922/publications.pdf

Version: 2024-02-01

178	5,270	34	65
papers	citations	h-index	g-index
182	182	182	7633
all docs	docs citations	times ranked	citing authors

#	Article	lF	CITATIONS
1	Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet, The, 2013, 381, 735-743.	6.3	455
2	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infectious Diseases, The, 2011, 11, 363-371.	4.6	345
3	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Medicine, 2013, 10, e1001510.	3.9	256
4	All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaborationA. International Journal of Epidemiology, 2012, 41, 433-445.	0.9	217
5	Natural history of chronic hepatitis B in co-infected patients. Journal of Hepatology, 2006, 44, S65-S70.	1.8	198
6	Early Impairment of Gut Function and Gut Flora Supporting a Role for Alteration of Gastrointestinal Mucosa in Human Immunodeficiency Virus Pathogenesis. Journal of Clinical Microbiology, 2008, 46, 757-758.	1.8	191
7	Response to combination antiretroviral therapy: variation by age. Aids, 2008, 22, 1463-1473.	1.0	188
8	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases, 2014, 58, 1312-1321.	2.9	140
9	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1899-1913.	1.1	137
10	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clinical Infectious Diseases, 2018, 66, 893-903.	2.9	105
11	Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART. PLoS ONE, 2010, 5, e13540.	1.1	94
12	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥200 Cells/µL in the Post–Combination Antiretroviral Therapy Era. Clinical Infectious Diseases, 2013, 57, 1038-1047.	2.9	92
13	Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. Thrombosis and Haemostasis, 2021, 121, 1054-1065.	1.8	87
14	Limited HIV Infection of Central Memory and Stem Cell Memory CD4+ T Cells Is Associated with Lack of Progression in Viremic Individuals. PLoS Pathogens, 2014, 10, e1004345.	2.1	76
15	Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection. Clinical Infectious Diseases, 2011, 52, 1164-1173.	2.9	70
16	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Eurosurveillance, 2015, 20, .	3.9	70
17	Clinical characteristics and predictors of mortality associated with COVID-19 in elderly patients from a long-term care facility. Scientific Reports, 2020, 10, 20834.	1.6	65
18	What Every Reader Should Know About Studies Using Electronic Health Record Data but May Be Afraid to Ask. Journal of Medical Internet Research, 2021, 23, e22219.	2.1	61

#	Article	IF	CITATIONS
19	Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in Predicting Virological Outcomes Over Time. PLoS ONE, 2010, 5, e11505.	1.1	56
20	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. Journal of Antimicrobial Chemotherapy, 2011, 66, 1886-1896.	1.3	56
21	Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons. Clinical Infectious Diseases, 2013, 57, 112-121.	2.9	56
22	A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy. Artificial Intelligence in Medicine, 2009, 47, 63-74.	3.8	55
23	Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report. Journal of Antimicrobial Chemotherapy, 2019, 74, 3399-3401.	1.3	54
24	Comparison between Rulesâ€Based Human Immunodeficiency Virus Type 1 Genotype Interpretations and Real or Virtual Phenotype: Concordance Analysis and Correlation with Clinical Outcome in Heavily Treated Patients. Journal of Infectious Diseases, 2003, 188, 194-201.	1.9	53
25	High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine, 2012, 41, 512-517.	1.1	52
26	Histopathological findings in a COVID-19 patient affected by ischemic gangrenous cholecystitis. World Journal of Emergency Surgery, 2020, 15, 43.	2.1	51
27	Prevalence and distribution of soil-transmitted helminth (STH) infections in urban and indigenous schoolchildren in Ortigueira, State of Parana, Brasil: implications for control. Tropical Medicine and International Health, 2000, 5, 302-307.	1.0	50
28	A Randomized Controlled Trial to Evaluate Antiretroviral Salvage Therapy Guided by Rules-Based or Phenotype-Driven HIV-1 Genotypic Drug-Resistance Interpretation With or Without Concentration-Controlled Intervention: The Resistance and Dosage Adapted Regimens (RADAR) Study. Clinical Infectious Diseases, 2005, 40, 1828-1836.	2.9	49
29	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. Clinical Infectious Diseases, 2017, 65, 1316-1326.	2.9	44
30	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infectious Diseases, The, 2012, 12, 119-127.	4.6	41
31	Update on epidemiology of HCV in Italy: focus on the Calabria Region. BMC Infectious Diseases, 2014, 14, S2.	1.3	40
32	Risk of Early Virological Failure of Onceâ€Daily Tenofovirâ€Emtricitabine plus Twiceâ€Daily Nevirapine in Antiretroviral Therapy–Naive HIVâ€Infected Patients. Clinical Infectious Diseases, 2008, 46, 1127-1129.	2.9	39
33	The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER Cohort. BMC Public Health, 2016, 16, 878.	1.2	37
34	Use of subcutaneous tocilizumab in patients with COVIDâ€19 pneumonia. Journal of Medical Virology, 2021, 93, 32-34.	2.5	37
35	Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/Î-1/4l Despite Effective HAART. PLoS ONE, 2015, 10, e0124741.	1.1	36
36	Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort. Journal of Antimicrobial Chemotherapy, 2005, 56, 190-195.	1,3	35

#	Article	IF	CITATIONS
37	Bcl-2 expression is moderately correlated with long-term variability of CD4 T-cell increase under successful highly active antiretroviral therapy. Aids, 2003, 17, 141-143.	1.0	33
38	Increasing Clinical Virulence in Two Decades of the Italian HIV Epidemic. PLoS Pathogens, 2009, 5, e1000454.	2.1	33
39	Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications. International Journal of Antimicrobial Agents, 2020, 55, 105891.	1.1	33
40	International Analysis of Electronic Health Records of Children and Youth Hospitalized With COVID-19 Infection in 6 Countries. JAMA Network Open, 2021, 4, e2112596.	2.8	33
41	Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2011, 66, 2372-2378.	1.3	30
42	Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors. Open Forum Infectious Diseases, 2015, 2, ofv043.	0.4	30
43	Use of colistin in adult patients: A cross-sectional study. Journal of Global Antimicrobial Resistance, 2020, 20, 43-49.	0.9	29
44	Effect of Highly Active Antiretroviral Therapy (HAART) and Hepatitis C Co-Infection on Hyperlipidemia in HIV-Infected Patients: A Retrospective Longitudinal Study. HIV Clinical Trials, 2002, 3, 451-461.	2.0	27
45	Prevalence and Risk Factors for Etravirine Resistance among Patients Failing on Non-Nucleoside Reverse Transcriptase Inhibitors. Antiviral Therapy, 2008, 13, 601-605.	0.6	26
46	Updateon different aspects of HCV variability: focus on NS5B polymerase. BMC Infectious Diseases, 2014, 14, S1.	1.3	25
47	Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-NaÃve Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir. HIV Clinical Trials, 2012, 13, 245-255.	2.0	24
48	Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility. Journal of Translational Medicine, 2021, 19, 79.	1.8	24
49	Predictors of AIDS-Defining Events Among Advanced Na $ ilde{A}^-$ ve Patients After HAART. HIV Clinical Trials, 2007, 8, 112-120.	2.0	22
50	Virological response to Salvage Therapy in HIV-Infected Persons Carrying the Reverse Transcriptase K65R Mutation. Antiviral Therapy, 2007, 12, 1175-1184.	0.6	22
51	Analysis of Severe Hepatic Events Associated with Nevirapine-Containing Regimens. Drug Safety, 2007, 30, 1161-1169.	1.4	21
52	Back to the origin of HCV 2c subtype and spreading to the Calabria region (Southern Italy) over the last two centuries: A phylogenetic study. Infection, Genetics and Evolution, 2014, 26, 352-358.	1.0	21
53	Virological Mechanisms in the Coinfection between HIV and HCV. Mediators of Inflammation, 2015, 2015, 1-7.	1.4	21
54	Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy. BMC Evolutionary Biology, 2017, 17, 70.	3.2	21

#	Article	IF	CITATIONS
55	No evidence of benefical effect of GB virus type C infection on the course of HIV infection. Aids, 2002, 16, 1430-1431.	1.0	21
56	Early Virological Failure after Tenofovir + Didanosine + Efavirenz Combination in HIV-Positive Patients upon Starting Antiretroviral Therapy. Antiviral Therapy, 2005, 10, 505-513.	0.6	21
57	Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy. Journal of Clinical Laboratory Analysis, 2001, 15, 43-46.	0.9	20
58	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	2.9	20
59	Protein and vitamin B6 intake are associated with liver steatosis assessed by transient elastography, especially in obese individuals. Clinical and Molecular Hepatology, 2017, 23, 249-259.	4.5	20
60	A 2021 Update on Syphilis: Taking Stock from Pathogenesis to Vaccines. Pathogens, 2021, 10, 1364.	1.2	19
61	Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting. Health Policy, 2003, 65, 261-267.	1.4	18
62	Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by Sars-Cov-2 infection: a real-life observational study. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662096301.	1.0	18
63	Efficacy and durability of two― <i>vs</i> . threeâ€drug integrase inhibitorâ€based regimens in virologically suppressed HIVâ€infected patients: Data from realâ€ife ODOACRE cohort. HIV Medicine, 2021, 22, 843-853.	1.0	18
64	Nasopharyngeal carcinoma: review of the literature with a focus on therapeutical implications. Infezioni in Medicina, 2015, 23, 224-9.	0.7	18
65	Immune Correlates of Virological Response in HIV-Positive Patients after Highly Active Antiretroviral Therapy (HAART). Viral Immunology, 2004, 17, 279-286.	0.6	17
66	Influence of Folate Serum Concentration on Plasma Homocysteine Levels in HIV-Positive Patients Exposed to Protease Inhibitors Undergoing HAART. Annals of Nutrition and Metabolism, 2006, 50, 247-252.	1.0	17
67	Updated prevalence of genotypic resistance among HIV-1 positive patients $na\tilde{A}$ -ve to antiretroviral therapy: a single center analysis. Journal of Medical Virology, 2008, 80, 747-753.	2.5	17
68	Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response. PLoS ONE, 2013, 8, e61436.	1,1	17
69	Liver fibrosis progression and clinical outcomes are intertwined. Medicine (United States), 2016, 95, e4091.	0.4	17
70	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2869-2878.	1.3	17
71	Discussion on critical points for a tailored therapy to cure hepatitis C virus infection. Clinical and Molecular Hepatology, 2019, 25, 30-36.	4.5	17
72	Predicting the magnitude of short-term CD4 <sup>+</sup> T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. Antiviral Therapy, 2010, 15, 165-175.	0.6	16

#	Article	IF	Citations
73	Unboosted Atazanavir for Treatment of HIV Infection. Drugs, 2012, 72, 1161-1173.	4.9	16
74	Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment. PLoS ONE, 2016, 11, e0162320.	1.1	16
75	Late-onset myocardial infarction and autoimmune haemolytic anaemia in a COVID-19 patient without respiratory symptoms, concomitant with a paradoxical increase in inflammatory markers: a case report. Journal of Medical Case Reports, 2020, 14, 246.	0.4	16
76	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection–Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study. Pathogens and Immunity, 2020, 5, 8.	1.4	16
77	Adiponectin serum level in chronic hepatitis C infection and therapeutic profile. World Journal of Hepatology, 2015, 7, 44.	0.8	16
78	The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists. Journal of Nephrology, 2015, 28, 393-402.	0.9	15
79	Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). International Journal of Epidemiology, 2017, 46, dyv192.	0.9	15
80	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. The Lancet Gastroenterology and Hepatology, 2017, 2, 427-434.	3.7	15
81	Increase of Vascular Endothelial Growth Factor and Decrease of MCP-1 and Some Updated Epidemiology Aspects of Cystic Echinococcosis Human Cases in Calabria Region. Mediators of Inflammation, 2018, 2018, 1-11.	1.4	15
82	Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus coâ€infected HIV patients with cirrhosis. Journal of Viral Hepatitis, 2019, 26, 1224-1228.	1.0	15
83	Predictors of Clinical Progression among HIV-1–Positive Patients starting HAART with CD4 <sup>+</sup> T-cell Counts ≥200 cells/mm <sup>3</sup> . Antiviral Therapy, 2007, 12, 941-948.	0.6	15
84	Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-NaÃ-ve Patients. International Journal of Molecular Sciences, 2016, 17, 1416.	1.8	14
85	Naive CD4+T Lymphocytes Express High Levels of Bcl-2 after Highly Active Antiretroviral Therapy for HIV Infection. AIDS Research and Human Retroviruses, 2000, 16, 1805-1807.	0.5	13
86	Plasma HIV Load and Proviral DNA Decreases After Two Standard Antiretroviral Regimens in HIV-Positive Patients Naive to Antiretrovirals. Current HIV Research, 2008, 6, 43-48.	0.2	13
87	Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. Aids, 2015, 29, 193-200.	1.0	13
88	Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor–based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials. Clinical Infectious Diseases, 2016, 63, 268-280.	2.9	13
89	Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals. Clinical and Molecular Hepatology, 2018, 24, 151-162.	4.5	13
90	Bacterial Ventilator-Associated Pneumonia in COVID-19 Patients: Data from the Second and Third Waves of the Pandemic. Journal of Clinical Medicine, 2022, 11, 2279.	1.0	13

#	Article	IF	Citations
91	Suppression of Hepatitis C Virus Replication is Maintained Long Term following Haart Therapy, in An Individual with HCV/HIV Co-Infection. Antiviral Therapy, 2004, 9, 139-142.	0.6	13
92	Evidence of Long-Term Suppression of Hepatitis B virus DNA by Tenofovir as Rescue Treatment in Patients Coinfected by HIV. Antiviral Therapy, 2008, 13, 341-348.	0.6	13
93	Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment. Multiple Sclerosis and Related Disorders, 2018, 20, 6-8.	0.9	12
94	Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients. BMC Infectious Diseases, 2018, 18, 518.	1.3	12
95	Potential implications of SARS-CoV-2 epidemic in Africa: where are we going from now?. BMC Infectious Diseases, 2020, 20, 412.	1.3	12
96	Is the Pendulum of Antimicrobial Drug Resistance Swinging Back after COVID-19?. Microorganisms, 2022, 10, 957.	1.6	12
97	Influence of Hepatitis C Genotypes on Lipid Levels in HIV-Positive Patients during Highly Active Antiretroviral Therapy. Antiviral Therapy, 2006, 11, 521-527.	0.6	12
98	Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naÃ-ve for lopinavir with limited exposure to previous protease inhibitors. Journal of Clinical Virology, 2006, 35, 414-419.	1.6	11
99	Comparison of a Rule-Based Algorithm with a Phenotype-Based Algorithm for the Interpretation of HIV Genotypes in Guiding Salvage Regimens in HIV-Infected Patients by a Randomized Clinical Trial: The Mutations and Salvage Study. Clinical Infectious Diseases, 2006, 42, 1470-1480.	2.9	11
100	Analysis of the persistence time of the SARS-CoV-2 virus in the cadaver and the risk of passing infection to autopsy staff. Medico-Legal Journal, 2021, 89, 40-53.	0.2	11
101	The Risk of Hepatocellular Carcinoma After Directly Acting Antivirals for Hepatitis C Virus Treatment in Liver Transplanted Patients: Is It Real?. Hepatitis Monthly, 2016, 16, e41933.	0.1	11
102	Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. International Journal of Antimicrobial Agents, 2007, 29, 185-190.	1.1	10
103	Knowledge of Human Cytomegalovirus Infection and Prevention in Pregnant Women: A Baseline, Operational Survey. Infectious Diseases in Obstetrics and Gynecology, 2017, 2017, 1-5.	0.4	10
104	Identification of human papillomavirus type 16 variants circulating in the Calabria region by sequencing and phylogenetic analysis of HPV16 from cervical smears. Infection, Genetics and Evolution, 2019, 68, 185-193.	1.0	10
105	Identification of pmrB mutations as putative mechanism for colistin resistance in A. baumannii strains isolated after in vivo colistin exposure. Microbial Pathogenesis, 2020, 142, 104058.	1.3	10
106	Multinational characterization of neurological phenotypes in patients hospitalized with COVID-19. Scientific Reports, 2021, 11, 20238.	1.6	10
107	Prevalence of Antibiotic Resistance Over Time in a Third-Level University Hospital. Microbial Drug Resistance, 2022, 28, 425-435.	0.9	10
108	Realâ€ife 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling. Journal of Medical Virology, 2018, 90, 1257-1263.	2.5	9

#	Article	IF	CITATIONS
109	Spontaneous and severe haematomas in patients with COVID-19 on low-molecular-weight heparin for paroxysmal atrial fibrillation. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020054.	0.5	9
110	Patterns of multi-drug resistant bacteria at first culture from patients admitted to a third level University hospital in Calabria from 2011 to 2014: implications for empirical therapy and infection control. Infezioni in Medicina, 2017, 25, 98-107.	0.7	9
111	Genotyping for Guiding Drug Choice in Human Immunodeficiency Virus-Infected Children Failing Multiple Antiretroviral Treatment Regimens. Pediatric Infectious Disease Journal, 2005, 24, 747-749.	1.1	8
112	Epstein–Barr and cytomegalovirus DNA salivary shedding correlate with longâ€ŧerm plasma HIV RNA detection in HIVâ€infected men who have sex with men. Journal of Medical Virology, 2016, 88, 1211-1221.	2.5	8
113	Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. Clinical Infectious Diseases, 2021, 73, 195-202.	2.9	8
114	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100Âcells/µL. Journal of the International AIDS Society, 2021, 24, e25726.	1.2	8
115	Evidence of Low Prevalence of Cystic Echinococcosis in the Catanzaro Province, Calabria Region, Italy. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1951-1954.	0.6	8
116	The Interplay between Host Defense, Infection, and Clinical Status in Septic Patients: A Narrative Review. International Journal of Molecular Sciences, 2022, 23, 803.	1.8	8
117	Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy. Journal of Clinical Laboratory Analysis, 2002, 16, 76-78.	0.9	7
118	SENV Infection in HIV-Positive Patients: Prevalence, Subtype Characterization, and Impact on HIV Disease Progression. AIDS Research and Human Retroviruses, 2003, 19, 1079-1082.	0.5	7
119	An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. Journal of Antimicrobial Chemotherapy, 2016, 71, 2928-2937.	1.3	7
120	Structural Modeling of New Polymorphism Clusters of HCV Polymerase Isolated from Directâ€Acting Antiviral Naà ve Patients: Focus on Dasabuvir and Setrobuvir Binding Affinity. ChemistrySelect, 2018, 3, 6009-6017.	0.7	7
121	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEATOO1/ANRS143 randomized trial. Journal of Antimicrobial Chemotherapy, 2020, 75, 628-639.	1.3	7
122	Is There Any Opportunity to Provide an HBV Vaccine Booster Dose before Anti-Hbs Titer Vanishes?. Vaccines, 2020, 8, 227.	2.1	7
123	Has COVID-19 changed the approach to HIV diagnosis?. Medicine (United States), 2021, 100, e27418.	0.4	7
124	The Effect of HIV-1 Resistance Mutations after First-Line Virological Failure on the Possibility to Sequence Antiretroviral Drugs in Second-Line Regimens. Antiviral Therapy, 2006, 11, 923-930.	0.6	7
125	Weight of Clinical and Social Determinants of Metabolic Syndrome in People Living with HIV. Viruses, 2022, 14, 1339.	1.5	7
126	Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: Prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. Journal of Medical Virology, 2004, 74, 29-33.	2.5	6

#	Article	IF	CITATIONS
127	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. Journal of Antimicrobial Chemotherapy, 2014, 69, 3085-3094.	1.3	6
128	Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4. Cells, 2019, 8, 416.	1.8	6
129	Ecology of Italian Protura. Pedobiologia, 2019, 73, 20-28.	0.5	6
130	Severe myocarditis due to influenza A(H1N1)pdm09 viral infection in a young woman successfully treated with intravenous zanamivir: A case report. Clinical Case Reports (discontinued), 2019, 7, 2336-2340.	0.2	6
131	Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection?. World Journal of Hepatology, 2016, 8, 815.	0.8	6
132	Role of the T2Dx magnetic resonance assay in patients with suspected bloodstream infection: a single-centre real-world experience. BMC Infectious Diseases, 2022, 22, 113.	1.3	6
133	Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide. Aids, 2007, 21, 1388-1389.	1.0	5
134	A case report of Schistosoma haematobiuminfection in a pregnant migrant raises concerns about lack of screening policies. Journal of Travel Medicine, 2016, 24, taw076.	1.4	5
135	Depression of lymphocyte activity during cutaneous leishmaniasis: a case report. Diagnostic Microbiology and Infectious Disease, 2018, 92, 230-234.	0.8	5
136	Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy). Medicina (Lithuania), 2020, 56, 101.	0.8	5
137	Therapy with RAS inhibitors during the COVID-19 pandemic. Journal of Cardiovascular Medicine, 2021, 22, 329-334.	0.6	5
138	A case report of pneumomediastinum in a COVID $\hat{a}$ patient treated with high $\hat{a}$ low nasal cannula and review of the literature: Is this a $\hat{a}$ esspontaneous $\hat{a}$ complication?. Clinical Case Reports (discontinued), 2021, 9, e04007.	0.2	5
139	Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine ATV/r in Patients with Preserved Renal Function. Open AIDS Journal, 2016, 10, 136-143.	0.1	5
140	Whole-genome analysis of SARS-CoV-2 in a 2020 infection cluster in a nursing home of Southern Italy. Infection, Genetics and Evolution, 2022, 99, 105253.	1.0	5
141	Cytokine Profile of Invasive Pulmonary Aspergillosis in Severe COVID-19 and Possible Therapeutic Targets. Diagnostics, 2022, 12, 1364.	1.3	5
142	HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations. Journal of Antimicrobial Chemotherapy, 2003, 52, 776-781.	1.3	4
143	CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load. Journal of Antimicrobial Chemotherapy, 2007, 59, 1141-1147.	1.3	4
144	HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure. Infection, Genetics and Evolution, 2013, 19, 349-360.	1.0	4

#	Article	IF	CITATIONS
145	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. Journal of Antimicrobial Chemotherapy, 2016, 71, 1352-1360.	1.3	4
146	2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings. Journal of Antimicrobial Chemotherapy, 2018, 73, 2186-2196.	1.3	4
147	Clinical outcomes of patients treated with intravenous zanamivir for severe influenza A(H1N1)pdm09 infection: a case report series. BMC Infectious Diseases, 2019, 19, 858.	1.3	4
148	The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy. Aids, 2019, 33, 315-326.	1.0	4
149	Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19. Travel Medicine and Infectious Disease, 2020, 37, 101826.	1.5	4
150	Characteristics, Management, and Outcomes of Elderly Patients with Diabetes in a Covid-19 Unit: Lessons Learned from a Pilot Study. Medicina (Lithuania), 2021, 57, 341.	0.8	4
151	Knowledge of HIV infection and transmission: a knowledge, attitudes, beliefs and practices (KABP) survey among a sample of students at the "Magna Graecia", University of Catanzaro. Annali Dell'Istituto Superiore Di Sanita, 2016, 52, 530-535.	0.2	4
152	Modifications in SENV DNA Detection and/or SENV Subtype Determination over a Prospective Follow-Up in a Cohort of HIV-Positive Patients: Is This a Moving Target?. Intervirology, 2004, 47, 350-354.	1.2	3
153	Cryptogenic Liver Diseases: Sailing by Sight from HIV Co-Infection with Hepatitis Viruses to HIV Mono-Infection Through the Pillars of Hercules. Current HIV Research, 2011, 9, 61-69.	0.2	3
154	Phylogenetic and Molecular Analyses of More Prevalent HCV1b Subtype in the Calabria Region, Southern Italy. Journal of Clinical Medicine, 2021, 10, 1655.	1.0	3
155	Histopathology and immunophenotyping of late onset cutaneous manifestations of COVID-19 in elderly patients: Three case reports. World Journal of Clinical Cases, 2021, 9, 5744-5751.	0.3	3
156	Utility of Molecular Identification and Quantitation of Bartonella Species with Species-Specific Real-Time PCR for Monitoring Treatment Response: A Case Series. Open Microbiology Journal, 2018, 12, 148-153.	0.2	3
157	HCV Antibody Prevalence and Genotype Evolution in a Teaching Hospital, Calabria Region, Southern Italy Over A Decade (2008-2018). Open Microbiology Journal, 2020, 14, 84-90.	0.2	3
158	Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfectionstatements of the First Italian Consensus Workshop. AIDS Reviews, 2005, 7, 161-7.	0.5	3
159	Is hand-grip another culprit for the risk of fractures in HIV-positive patients?. New Microbiologica, 2016, 39, 61-4.	0.1	3
160	Listeria infection after treatment with alemtuzumab: a case report and literature review. Would antibiotic prophylaxis be considered?. Infezioni in Medicina, 2020, 28, 258-262.	0.7	3
161	Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice. World Journal of Gastroenterology, 2022, 28, 1226-1238.	1.4	3
162	A king in the CASTLE? Optimum initial HIV protease inhibitor. Lancet, The, 2008, 372, 604-606.	6.3	2

#	Article	IF	Citations
163	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. Digestive and Liver Disease, 2021, 53, 1603-1609.	0.4	2
164	Effect of directly acting antivirals for hepatitis C virus infection on proprotein convertase subtilisin/kexin type 9 level. Health Science Reports, 2021, 4, e273.	0.6	2
165	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. Journal of Healthcare Engineering, 2021, 2021, 1-10.	1.1	2
166	Prevalence of parasitic infections in migrants: do official symptom-driven guidelines apply to the current situation?. Infezioni in Medicina, 2018, 26, 347-355.	0.7	2
167	Risk factors for hepatitis B and C among healthy population: a community-based survey from four districts of Southern Italy. Infezioni in Medicina, 2020, 28, 223-226.	0.7	2
168	Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients Treated with Standard Dose of Dexamethasone or High Dose of Methylprednisolone. Biomedicines, 2022, 10, 1548.	1.4	2
169	Effectiveness of Intramuscular Chlorpromazine for Rapid Treatment of Psychomotor Agitation. Journal of Clinical Psychopharmacology, 2021, 41, 613-614.	0.7	1
170	The Disagreement Among Methods to Evaluate Glomerular Filtration Rate in HIV-Infected Patients Naive to Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2012, 28, 637-640.	0.5	0
171	Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort. BMC Infectious Diseases, 2017, 17, 212.	1.3	О
172	Multidisciplinary approach to a septic COVIDâ€19 patient undergoing venoâ€venous extracorporeal membrane oxygenation and receiving thoracic surgery. Clinical Case Reports (discontinued), 2021, 9, e04828.	0.2	0
173	Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience. Medicine (United States), 2021, 100, e27418.	0.4	О
174	Changing epidemiology of hepatitis C in Italy: a population-based survey in a historically high endemic area. Minerva Medica, 2021, , .	0.3	0
175	Outcome of HBV screening and vaccination in a migrant population in southern Italy. Infezioni in Medicina, 2021, 29, 236-241.	0.7	О
176	Role of IgG and IgM and proinflammatory aspecific markers in the diagnosis and prognosis of COVID-19 patients stratified by number of positive SARS-CoV-2 genes. Minerva Medica, 2022, , .	0.3	0
177	$598\hat{a} \in f$ Are risk scores sufficient to stratify patients undergoing lead extraction? A single-centre analysis. European Heart Journal Supplements, 2021, 23, .	0.0	0
178	Molecular characterization of <i>Schistosoma</i> infections in African migrants: identification of a <i>Schistosoma haematobium-bovis</i> hybrid in bladder biopsies. Journal of Travel Medicine, 2021, , .	1.4	0